-
Danish Pharmacovigilance Update 30 April 2014
| 07 May 2014 |
In the April issue of Danish Pharmacovigilance Update:
-
Danish Pharmacovigilance Update 29 January 2014
| 14 April 2014 |
In this issue of Danish Pharmacovigilance Update
-
Danish Pharmacovigilance Update 27 March 2014
| 10 April 2014 |
In this issue of Danish Pharmacovigilance Update
-
Danish Pharmacovigilance Update 27 February 2014
| 01 April 2014 |
In this issue of Danish Pharmacovigilance Update: Further restrictions on the use of osteoporosis medicine strontium ranelate (Protelos®), Anticoagulant therapy to be stopped before initiating treatment with the new oral anticoagulants (NOACs).
-
Danish Pharmacovigilance Update 31 October 2013
| 05 March 2014 |
In this issue of Danish Pharmacovigilance Update: The risk of blood clots from the use of contraceptive pills is low regardless of type, Report of cardiac arrest in association with the use of flecainide (Tambocor®).
-
Danish Pharmacovigilance Update 19 December 2013
| 17 February 2014 |
In this issue of Danish Pharmacovigilance Update: Patients with mechanical heart valves should not be treated with the new oral anticoagulants Pradaxa®, Xarelto® and Eliquis®.
-
Danish Pharmacovigilance Update 28 November 2013
| 03 February 2014 |
In this issue of Danish Pharmacovigilance Update: Ciprofloxacin and the risk of tendon disorders, risk of blood clots from the use of the cancer medicine ponatinib and reporting of adverse reactions to the Danish Health and Medicines Authority.
-
Danish Pharmacovigilance Update, 26 September 2013
| 21 November 2013 |
In this issue of Danish Pharmacovigilance Update: Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are associated with risk of capillary leak syndrome.
-
Danish Pharmacovigilance Update, 29 August 2013
| 23 October 2013 |
In this issue of Danish Pharmacovigilance Update: Cases of acquired haemophilia following treatment with clopidogrel (Plavix® etc.)
-
Danish Pharmacovigilance Update, 27 June 2013
| 24 July 2013 |
In this issue of Danish Pharmacovigilance Update: The benefits of medicines for the treatment of acne (Diane® Mite and others) continue to outweigh the risks of use within the indication.
-
Voluntary Harmonisation Procedure (VHP) for the assessment of multinational clinical trial applications
| 09 July 2013 |
The Voluntary Harmonisation Procedure is a procedure which makes it possible to obtain a coordinated assessment of an application for a clinical trial that is to take place in several European countries.
-
Danish Pharmacovigilance Update, 23 May 2013
| 17 June 2013 |
In this issue of Danish Pharmacovigilance Update: Cases of necrotising fasciitis associated with the use of bevacizumab (Avastin®).
-
Danish Pharmacovigilance Update, 25 April 2013
| 29 May 2013 |
In this issue of Danish Pharmacovigilance Update: Cerebral haemorrhage in association with the use of methylphenidate (Ritalin® etc.).
-
Painkillers to be prescription only in Denmark from 30 September 2013
| 28 May 2013 |
The Danish Health and Medicines Authority has decided that large packs of mild painkillers will be prescription-only in Denmark from 30 September 2013. From this date, it will only be possible to buy small packs of mild painkillers over the counter. There will be no changes to dispensing status of the medicines that can be bought over the counter after 30 September.
-
Danish Pharmacovigilance Update, 21 March 2013
| 25 April 2013 |
In this issue of Danish Pharmacovigilance Update: Depressive and suicidal thoughts following discontinuation of varenicline (Champix®).
-
Danish Pharmacovigilance Update, 21 February 2013
| 25 April 2013 |
In this issue of Danish Pharmacovigilance Update: Cardiovascular monitoring when initiating and re-initiating treatment with fingolimod (Gilenya®).
-
Painkillers to be prescription only in Denmark
| 08 April 2013 |
In Denmark, it will soon only be possible to buy large packs of mild painkillers when prescribed by a doctor. The aim is to reduce poisoning incidents and the need for liver transplants.
-
Danish Pharmacovigilance Update, 17 January 2013
| 26 March 2013 |
In this issue of Danish Pharmacovigilance Update: The Pharmacovigilance Risk Assessment Committee, PRAC, finds that the risks outweigh the benefits from the use of Tredaptive®
-
Review concluded regarding general reimbursement for Valsartan/Hydrochlorothiazide "Actavis"
| 08 March 2012 |
We have completed our review of an application for general reimbursement for Valsartan/Hydrochlorothiazide "Actavis". The product is neither eligible for general nor general conditional reimbursement.
-
Comments received on the reassessment of reimbursement status of antidiabetic medicines (ATC group A10)
| 06 March 2012 |
The Danish National Board of Health has received a number of comments from stakeholders about the Reimbursement Committee's discussion of the reimbursement status of antidiabetic medicines (ATC group A10).
